Reata Pharmaceuticals is a biotechnology business based in the US. Reata Pharmaceuticals shares (RETA) are listed on the NASDAQ and all prices are listed in US Dollars. Reata Pharmaceuticals employs 321 staff and has a trailing 12-month revenue of around $23.5 million.
Our top picks for where to buy Reata Pharmaceuticals stock
How to buy Reata Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – RETA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Reata Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Reata Pharmaceuticals stock price (NASDAQ: RETA)
Use our graph to track the performance of RETA stocks over time.Reata Pharmaceuticals shares at a glance
Latest market close | $172.36 |
---|---|
52-week range | $168.67 - $172.46 |
50-day moving average | $160.97 |
200-day moving average | $97.64 |
Wall St. target price | $172.40 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.60 |
Is it a good time to buy Reata Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Reata Pharmaceuticals price performance over time
Historical closes compared with the close of $172.36 from 2023-09-26
1 week (2024-08-27) | N/A |
---|---|
1 month (2024-08-03) | N/A |
3 months (2024-06-03) | N/A |
6 months (2024-03-03) | N/A |
1 year (2023-09-07) | 1.30% |
---|---|
2 years (2022-09-07) | 536.72% |
3 years (2021-09-07) | 53.65% |
5 years (2019-09-06) | 100.19% |
Reata Pharmaceuticals financials
Revenue TTM | $23.5 million |
---|---|
Gross profit TTM | $-167,627,000 |
Return on assets TTM | -37.66% |
Return on equity TTM | -112.39% |
Profit margin | 0% |
Book value | $2.31 |
Market Capitalization | $6.6 billion |
TTM: trailing 12 months
Reata Pharmaceuticals share dividends
We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.
Reata Pharmaceuticals share price volatility
Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $168.67 up to $172.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.4194. This would suggest that Reata Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Reata Pharmaceuticals overview
Reata Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co. , Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc.
Frequently asked questions
What percentage of Reata Pharmaceuticals is owned by insiders or institutions?Currently 4.101% of Reata Pharmaceuticals shares are held by insiders and 88.465% by institutions. How many people work for Reata Pharmaceuticals?
Latest data suggests 321 work at Reata Pharmaceuticals. When does the fiscal year end for Reata Pharmaceuticals?
Reata Pharmaceuticals's fiscal year ends in December. Where is Reata Pharmaceuticals based?
Reata Pharmaceuticals's address is: 5320 Legacy Drive, Plano, TX, United States, 75024 What is Reata Pharmaceuticals's ISIN number?
Reata Pharmaceuticals's international securities identification number is: US75615P1030 What is Reata Pharmaceuticals's CUSIP number?
Reata Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75615P103
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
10 best brokerage accounts for buying stocks, options and more in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question